GlassScriptPhysician profile
William A Mccann
NPI 1922098250
$486,450.18
in general payments reported to CMS, 2019-2025
30 companies · $130K in 2025
The $130K reported for 2025 was more than what 98% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82K · 2020: $45K · 2021: $53K · 2022: $64K · 2023: $60K · 2024: $52K · 2025: $130K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $180K · Consulting Fee: $38K · Travel and Lodging: $15K · Food and Beverage: $8,891 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $180,211.60 |
| Consulting Fee | $38,284.79 |
| Travel and Lodging | $15,102.84 |
| Food and Beverage | $8,890.65 |
| Education | $109.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $325,918.33 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Regeneron Healthcare Solutions, INC. | $54,230.45 | 2019-2024 | Dupixent |
| Ars Pharmaceuticals Operations, INC. | $44,918.96 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $26,071.97 | 2022-2025 | |
| Genentech USA, INC. | $10,675.52 | 2019-2025 | Xolair, Xofluza |
| Genzyme Corporation | $9,733.13 | 2019-2023 | |
| Amgen INC. | $4,964.35 | 2022-2025 | Tezspire |
| Aimmune Therapeutics, INC. | $3,419.71 | 2021-2022 | |
| Astrazeneca Uk Limited | $1,860.00 | 2019 | |
| Glaxosmithkline, LLC. | $876.43 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $849.02 | 2020-2021 | |
| Alk-Abello, INC | $630.42 | 2019-2023 | Grastek, Ragwitek, Odactra |
| Blueprint Medicines Corporation | $588.69 | 2023-2025 | Ayvakit |
| Eyevance Pharmaceuticals LLC | $500.00 | 2020 | |
| Csl Behring | $248.69 | 2019-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $158.59 | 2021-2022 | |
| Siemens Medical Solutions USA, INC. | $143.45 | 2023 | |
| Optinose US, INC. | $136.84 | 2019-2022 | |
| Aquestive Therapeutics, INC. | $119.22 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $109.75 | 2019-2021 | |
| Biocryst US Sales Co., LLC | $70.20 | 2021 | |
| Horizon Therapeutics Plc | $50.97 | 2019 | |
| Hospira, INC. | $49.67 | 2020-2021 | |
| Pfizer INC. | $27.92 | 2021-2022 | |
| Adma Biomanufacturing LLC | $21.29 | 2024 | |
| Jubilant Hollisterstier LLC | $20.71 | 2024 | |
| Kaleo, INC. | $18.83 | 2020 | |
| Aytu Biopharma, INC. | $13.61 | 2020 | |
| Bio Products Laboratory USA, INC. | $12.51 | 2021 | |
| Mylan Specialty L.P. | $10.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Mccann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.